N/A N=88 Gastrointestinal Myoelectric Activity Protocol, the G-Tech EEnG Protocol
Gastrointestinal Diseases
Primary: Device Success Defined as the Ability to Record Myoelectric Signals in Study Subjects. — 88 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=105 A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis
Keratosis, Actinic
Primary: Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling…
N/A N=19 Smartphone and 3D Printing Based Home Rehabilitation System for Chronic Stroke
Stroke
Primary: Repetitions Completed for Each Activity in the mRehab Home Program — 282.06; NA; 289.44; NA repetitions
N/A N=28 Assessing Acceptability, Cost, and Efficacy of STELLA-Support Via Technology
Dementia · Alzheimer Disease · Caregiver Burnout
Primary: Revised Memory and Behavior Problems Checklist — NA; 41.5; NA; 39.5 units on a scale
Phase 3 N=69 Liraglutide in Type 1 Diabetes
Type 1 Diabetes
Primary: HbA1c (%) — 7.92; 7.48; 7.45; 7.58 Percent of Hemoglobin (%)
Phase 2 N=159 A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor
Advanced Breast Cancer
Primary: Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessment — 7.4; 2.0 Months
Phase 3 N=52 Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan
Nausea · Vomiting
Primary: Complete Response (CR) — 4; 11; 4 Participants
N/A N=11 Blossom Smart Expander Technology in Breast Reconstruction in Participants With Breast Cancer Undergoing Mastectomy
Breast Carcinoma · Breast Disorder
Primary: Time to Full Expansion Defined as Number of Days Until Desired Breast Tissue Expansion Volume is Achieved — 13 days
N/A N=986 Clinical Evaluation of VeriSee AMD in Screening for Age-Related Macular Degeneration
Macular Degeneration, Age Related · Maculopathy, Age Related
Primary: Sensitivity — 90 percent
N/A N=347 Communicating Health Information and Improving Coordination With Primary Care
Hypertension · Dyslipidemias · Diabetes
Primary: Undertreatment of Hypertension (>=140/90 mmHg), Dyslipidemia (LDL >=160 mg/dL or Triglyceride >=150 mg/dL), and/or Glucose Intolerance (if Prediabetes, Hemoglobin A1c…
Phase 4 N=25 Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52)
Chronic Rhinosinusitis With Nasal Polyps
Primary: Percentage of Participants With NPS Improvement From Baseline >=1 at Week 24 — 92.0 percentage of participants
Phase 1 N=30 Renal Impairment Study of PF-06700841
Healthy Volunteer · Renal Impairment
Primary: Maximum Observed Plasma Concentration (Cmax) of PF-06700841 Following Single Oral Dose Administration in Participants With Renal Impairment and in Healthy Participants…
Phase 3 N=400 Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)
Carcinoma, Hepatocellular
Primary: Overall Survival — 8.7; 6.8 months
N/A N=84 Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer
Breast Cancer
Primary: Time to Treatment Failure (TTF) for Talazoparib — 8.5 Months
Phase 2 N=81 COVID-19 Protection After Transplant Pilot Study
Kidney Transplant Recipients
Primary: Proportion of Recipients Who Achieve an Antibody Response >50 U/mL After the Third Dose of mRNA COVID-19 Vaccine — 69.1 Percentage of participants with response